Comparative Pharmacology
Head-to-head clinical analysis: NYSTOP versus VANOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYSTOP versus VANOBID.
NYSTOP vs VANOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular ions and cell death.
Vancomycin inhibits cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing cross-linking.
Apply a thin layer to affected area 2-3 times daily or as directed. Nystatin is not absorbed systemically; topical use only.
500-1000 mg orally every 12 hours or 250 mg every 6 hours.
None Documented
None Documented
Not applicable for systemic pharmacokinetics due to minimal absorption; local half-life on mucosal surfaces is not defined. For intravenous administration (not approved), the terminal half-life is approximately 2-4 hours, but this route is not clinically used.
Terminal elimination half-life: 8-12 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Nystatin is not absorbed from the gastrointestinal tract or intact skin/mucous membranes; when administered topically or orally, it is excreted almost entirely in feces as unchanged drug (>99%). Less than 1% is excreted renally if ingested. No quantified biliary excretion reported.
Renal (unchanged): 30-50% within 24 hours; Biliary/fecal: 15-25% as metabolites; remainder undergoes hepatic metabolism.
Category C
Category C
Antifungal
Antifungal and Corticosteroid Combination